BRPI0412798A - uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação - Google Patents

uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação

Info

Publication number
BRPI0412798A
BRPI0412798A BRPI0412798-6A BRPI0412798A BRPI0412798A BR PI0412798 A BRPI0412798 A BR PI0412798A BR PI0412798 A BRPI0412798 A BR PI0412798A BR PI0412798 A BRPI0412798 A BR PI0412798A
Authority
BR
Brazil
Prior art keywords
combination
antagonist
agent
pharmaceutical composition
inhibiting
Prior art date
Application number
BRPI0412798-6A
Other languages
English (en)
Inventor
Jocelyn Holash
Robert Jaffe
Limin Hu
George D Yancopoulos
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118812&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412798(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Publication of BRPI0412798A publication Critical patent/BRPI0412798A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

"USO DE UMA COMBINAçãO DE UM ANTAGONISTA DE FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR E UM AGENTE ANTIPROLIFERATIVO, MéTODO DE INIBIR OU REDUZIR O CRESCIMENTO DE TUMOR, COMPOSIçãO FARMACêUTICA, USO DE UMA COMBINAçãO DE UM ANTAGONISTA DE VEGF E UM AGENTE QUIMIOTERAPêUTICO, E, ARTIGO DE FABRICAçãO". Métodos de tratar câncer e/ou reduzir ou inibir o crescimento de tumor em um indivíduo em necessidade deste, que compreende administrar a composição farmacêutica que compreende um antagonista fator de crescimento celular endotelial vascular (VEGF), tais como uma armadilha de VEGF, um agente anti-proliferativo, tal como taxol e um carreador farmaceuticamente aceitável.
BRPI0412798-6A 2003-07-25 2004-07-23 uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação BRPI0412798A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49000203P 2003-07-25 2003-07-25
US49397103P 2003-08-08 2003-08-08
PCT/US2004/023815 WO2005011734A2 (en) 2003-07-25 2004-07-23 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0412798A true BRPI0412798A (pt) 2006-09-26

Family

ID=34118812

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412798-6A BRPI0412798A (pt) 2003-07-25 2004-07-23 uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação

Country Status (17)

Country Link
US (1) US7354579B2 (pt)
EP (1) EP1648428A2 (pt)
JP (1) JP5355856B2 (pt)
KR (1) KR101175990B1 (pt)
AR (1) AR046510A1 (pt)
AU (1) AU2004261165C1 (pt)
BR (1) BRPI0412798A (pt)
CA (1) CA2529742C (pt)
IL (1) IL172406A (pt)
MX (1) MXPA05013642A (pt)
MY (1) MY149169A (pt)
NO (1) NO20060924L (pt)
NZ (1) NZ544570A (pt)
RU (1) RU2353353C2 (pt)
TW (1) TWI351953B (pt)
UY (1) UY28438A1 (pt)
WO (1) WO2005011734A2 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004247095A1 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for tumor regression
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1853298A2 (en) * 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
MX2007009960A (es) * 2005-02-18 2008-03-11 Abraxis Bioscience Inc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
EA200801170A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
PL2371865T3 (pl) 2006-04-07 2018-02-28 Aerpio Therapeutics, Inc. Przeciwciała wiążące ludzką białkową fosfatazę tyrozynową beta (HPTP-β) oraz ich zastosowania
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
SI2364691T1 (sl) 2006-06-16 2013-08-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP2125002A4 (en) * 2007-03-14 2011-02-23 Mayo Foundation TREATMENT OF SKIN CANCER
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
LT5610B (lt) 2007-12-17 2009-11-25 Uab Baltec Cnc Technologies, , Kompleksinė sveikatinimo ir sporto įrangos sistema ir jos įgyvendinimo būdas
ES2958968T3 (es) * 2008-06-17 2024-02-16 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
EP2310006A4 (en) 2008-07-03 2012-04-25 Mayo Foundation TREATMENT OF CANCER
SG172313A1 (en) 2009-07-06 2011-07-28 Akebia Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
CN103140225A (zh) 2010-06-04 2013-06-05 阿布拉科斯生物科学有限公司 治疗胰腺癌的方法
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2792062T3 (es) 2011-05-09 2020-11-06 Mayo Found Medical Education & Res Tratamientos contra el cáncer
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
EP3154595A4 (en) 2014-06-16 2018-01-24 Mayo Foundation for Medical Education and Research Treating myelomas
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
CA2998673C (en) 2015-09-23 2023-12-12 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research INTERFERON CANCER TREATMENT METHODS
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
US10654922B2 (en) * 2016-05-13 2020-05-19 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
KR20190053203A (ko) 2016-09-01 2019-05-17 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｔ－세포 암을 표적화하는 방법 및 조성물
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
US11311631B2 (en) 2016-09-06 2022-04-26 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
EP3589324A1 (en) 2017-03-03 2020-01-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
JP2022530657A (ja) 2019-04-29 2022-06-30 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
AU2020393842A1 (en) 2019-11-25 2022-06-16 The Regents Of The University Of California Long-acting VEGF inhibitors for intraocular neovascularization
IL308505A (en) 2021-05-17 2024-01-01 Regeneron Pharma Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
US20230295266A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
US20240024420A1 (en) 2022-03-15 2024-01-25 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE269357T1 (de) * 1999-04-28 2004-07-15 Univ Texas Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
ES2237429T3 (es) * 1999-06-08 2005-08-01 Regeneron Pharmaceuticals, Inc. Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
AU2004247095A1 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for tumor regression

Also Published As

Publication number Publication date
KR20060028654A (ko) 2006-03-30
WO2005011734A2 (en) 2005-02-10
WO2005011734A3 (en) 2005-04-14
KR101175990B1 (ko) 2012-08-23
TW200524589A (en) 2005-08-01
RU2353353C2 (ru) 2009-04-27
AU2004261165B2 (en) 2009-07-16
MXPA05013642A (es) 2006-03-10
TWI351953B (en) 2011-11-11
US20050032699A1 (en) 2005-02-10
AR046510A1 (es) 2005-12-14
JP5355856B2 (ja) 2013-11-27
JP2007500131A (ja) 2007-01-11
IL172406A0 (en) 2006-04-10
NO20060924L (no) 2006-04-25
CA2529742A1 (en) 2005-02-10
MY149169A (en) 2013-07-31
AU2004261165A1 (en) 2005-02-10
IL172406A (en) 2016-04-21
UY28438A1 (es) 2004-11-08
AU2004261165C1 (en) 2009-12-17
US7354579B2 (en) 2008-04-08
EP1648428A2 (en) 2006-04-26
NZ544570A (en) 2008-08-29
CA2529742C (en) 2012-09-18
RU2006105496A (ru) 2006-06-10

Similar Documents

Publication Publication Date Title
BRPI0412798A (pt) uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação
ATE290882T1 (de) Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
BR0207378A (pt) Tratamento de câncer
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
ATE448812T1 (de) Beschichtung von stents mit verzögerter wirkstofffreisetzung
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
MY127369A (en) Quinazoline derivatives
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
CO5050297A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
NZ547191A (en) Treatment of proliferative diseases using an antisense IAP oligomer and chemotherapeutic agent
MXPA05008478A (es) Heterociclos sustituidos.
WO2002058694A3 (en) Method of treating hematologic tumors and cancers using beta lapachone
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
MY138883A (en) Use of asiatic acid for treatment of cencer
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
SE0003476D0 (sv) Compounds
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
IS6130A (is) Bólgueyðandi meðhöndlun fyrir bólgu tengt smit
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
SE0100684D0 (sv) New subject-matter
MY150767A (en) Polyethylene glycol modifications of thymosin alpha 1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL